secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARVARD BIOSCIENCE INC (HBIO)
CIK:        0001123494
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001171843-22-007231
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harvard Bioscience Q3 revenue down 9% to $26.9M; GAAP operating loss $3.8M vs income $0.5M
--------------------------------------------------------------------------------

- GAAP diluted EPS ($0.08) vs ($0.00); adjusted diluted EPS ($0.01) vs $0.06.
- Pre-clinical product sales fell 17% YoY; cellular/molecular grew 6%; currency headwind ~$1.0M.
- Q4 revenue guided to ~$30M with adjusted operating margin 14-15% (Q3 margin 2.6%).
- Portfolio optimization to yield ~$4.0M annual gross margin improvement and ~$1.5M opex reduction entering 2023.
- Net debt increased to $45.0M from $40.9M YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1123494/000117184322007231/0001171843-22-007231-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1123494/000117184322007231/f8k_110822.htm
  HTML page:      https://secwatch.observer/filing/0001171843-22-007231

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer